Category - Markets

William Blair upgraded Zogenix (NASAQ:ZGNX) to “outperform” and Stifel more than doubled its price target to $55 from $26 after the company unveiled strongly positive Phase 3 data for ZX008 (fenfluramine) in Dravet...

Maxim Group raised its price target for BeiGene (NASDAQ:BGNE) to $120 from $77 after the company announced preliminary data from its ongoing Phase 1/2 study of BGB-A317 (PD-1 antibody) in Chinese patients with advanced...

Paradigm Capital launched coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with a “buy” rating and price target of $2.25. The stock closed at 95 cents on Sept. 27. Profound is commercializing the TULSA-PRO medical...

BTIG initiated coverage of Oxford Immunotec Global (NASDAQ:OXFD) with a “buy” rating and $21 price target. The stock closed at $16.76 on Sept. 27. Oxford already has a successful product – TSPOT.TB test, which is...

Roth Capital Partners reinitiated coverage of Savara (NASDAQ:SVRA) with a “buy” rating and $40 price target. The stock closed at $9.24 on Sept. 26. Savara is developing inhalable formulations of therapeutics with proven...

H.C. Wainwright raised its price target for Fibrocell Science (NASDAQ:FCSC) to $7.60 from $5.70 after the company announced first efficacy data from a single injection of FCX-007 in patients with recessive dystrophic...

H.C. Wainwright initiated coverage of Corium International (NASDAQ:CORI) with a “buy” rating and $15 price target. The stock closed at $10.88 on Sept. 25. Corium is a pure-play transdermal (TD) patch dug delivery...

Leerink upgraded for Dova Pharmaceuticals (NASDAQ:DOVA) to “outperform” from “market perform” and raised its price target to $32 from $24 after competitor, Shionogi, announced results from a Phase 3 trial. Shares of...

Roth Capital Partners launched coverage of AIT Therapeutics (OTC:AITB) with a “buy” rating and $14 price target. The stock closed at $5.75 on Sept. 25. AIT is utilizing nitric oxide-based inhalation technology to treat...

Stifel downgraded Genocea Biosciences (NASDAQ:GNCA) to “hold” from “buy” and slashed its price target to $2.50 from $15 after the company shifted its strategic focus. The stock closed at $5.33 on Sept. 25. “We believe...